Pacer Advisors Inc. Purchases 1,269 Shares of IDEXX Laboratories, Inc. $IDXX

Pacer Advisors Inc. grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,965 shares of the company’s stock after purchasing an additional 1,269 shares during the quarter. Pacer Advisors Inc.’s holdings in IDEXX Laboratories were worth $9,448,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $26,000. Park Place Capital Corp bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $29,000. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories during the second quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of IDEXX Laboratories during the third quarter worth approximately $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $562.09 on Monday. The firm has a market capitalization of $44.34 billion, a PE ratio of 41.39, a PEG ratio of 3.07 and a beta of 1.56. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The business’s 50 day moving average is $561.66 and its 200-day moving average is $620.14.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, UBS Group cut their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.